NIH to fund up to $1.5m in cannabinoid research


ENFLEUR is encouraged by the National Institutes of Health (NIH) announcement of its intent to fund up to $1.5m in research into the analgesic properties of not only CBD, but some of the lesser known cannabinoids and terpenes. This is indicative of the federal governments interest in cannabis’ long-touted ability to help manage pain. Early cannabinoid studies focused largely on the psychoactive component of cannabis, namely THC. The recent explosion of research in CBD demonstrates its remarkable therapeutic range, from its psychopharmacological applications (anti-anxiety, anti-depressant, anti-psychotic, and PTSD), promising studies in neurodegenerative diseases (Alzheimer’s disease and Parkinson’s disease), skin complaints (eczema, acne), and chemical dependency (nicotine, alcohol, cocaine, heroin, methamphetamine) to name just some. In light of the results of these CBD studies, it is unsurprising that the government would wish to continue funding research into CBD, as well as to invest in the potential therapeutic applications of other cannabinoids, namely CBG, CBN, CBC, as well as ten named terpenes. The NIH grant notice can be viewed here with an earliest estimated award date of September 10, 2019.